|
Match
|
Document |
Document Title |
|
|
6180095 |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric prodrugs are preferably of the formula: ##STR1## wherein: L 1 is a bifunctional...
|
|
|
6174996 |
Hybrid interferon τ/type I interferon polypeptides
The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-τ) polypeptide and a C-terminal region derived from another type I interferon...
|
|
|
6168787 |
Pluripotent vaccine against enveloped viruses
The present invention is directed to compositions and methods for the induction of immune responses in mammals against enveloped animal viruses. More particularly, the invention provides vaccine...
|
|
|
6156729 |
Leukemia inhibitory factor for use in modulating inflammation and pain
A method for inhibiting and/or reducing inflammation and/or pain in an individual is provided. The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in...
|
|
|
6150327 |
Conjugate of an active agent, a polyether and possibly a native protein regarded as acceptable by the body
This invention relates to the use of a conjugate comprising an active substance and a native protein which is not recognized as foreign protein for the production of a pharmaceutical preparation...
|
|
|
6143292 |
Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
A method of treating a human cancer patient having a solid tumor comprising malignant cells is disclosed, wherein the patient having undergone a cancer therapy regimen comprising allogeneic stem...
|
|
|
6117423 |
Highly purified species of human leukocyte interferon
Disclosed is purified human leukocyte interferon, including human leukocyte interferon obtained from Namalva cells ("Namalva interferon") which, for the first time, is shown to contain a mixture of...
|
|
|
6114145 |
Synferon, a synthetic interferon
The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon...
|
|
|
6096547 |
Method and transgenic plant for producing mammalian peptides
Constructs are provided for expression of physiologically active mammalian proteins in plant cells, either in culture or under cultivation. The constructs provide a promoter functional in a plant...
|
|
|
6096320 |
Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica
New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are...
|
|
|
6096301 |
Combined interferon/antiestrogen therapy for treatment of breast cancer
Proliferation of breast cancer is treated by a combined type I interferon/non-steroidal antiestrogen therapy. Preferably antiestrogen treatment is sequential to treatment with interferon.
|
|
|
6086869 |
Use of interferon-β or γ to treat retinal edema
The invention provides methods for treating retinal edema, particularly cystoid macular edema, employing interferon (IFN)-α, IFN-β, or IFN-γ. The IFN may be administered locally, orally, or...
|
|
|
6083534 |
Pharmaceutical compositions for controlled release of soluble receptors
A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a...
|
|
|
6071510 |
Modified amino acids and compositions comprising the same for delivering active agents
The present invention provides modified amino acids for delivering active agents, and particularly biologically or chemically active agents. The preferred modified amino acids of the present...
|
|
|
6063373 |
Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
An improved method for the prevention of the inactivation of natural killer (NK) cells and the enhanced activation of NK cells in the presence of monocytes using a combination of a natural killer...
|
|
|
6060450 |
Method for treatment of autoimmune diseases
Methods of treating autoimmune disorders, such as multiple sclerosis, are disclosed. The methods employ administration of interferon-tau (IFNτ) in a therapeutically-effective dose.
|
|
|
6042826 |
Method for inducing apoptosis of primary central nervous system B cell lymphomas
A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking...
|
|
|
6036949 |
Treatment of fibromyalgia with low doses of interferon
A method is described for using interferon in the treatment of human patients afflicted with fibromyalgia to alleviate one or more symptoms associated with that disease state. Fibromyalgia positive...
|
|
|
6036956 |
Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease
The present invention is directed to immunotherapeutic methos for treating systemic lupus erythematosus (SLE) by administerring polyclonal or monoclonal antibodies specific for gamma interferon...
|
|
|
6030609 |
Method and composition for treating paramyxovirus
The present invention relates to a method of treating respiratory syncytial virus (RSV) through the exogenous administration of recombinant or natural interferon-beta (IFN-β) to lung epithelial...
|
|
|
6017540 |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
|
|
|
6013253 |
Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination...
|
|
|
6007805 |
Use of interferon subtype alpha-8 (IFN-α.sub.8) to treat viral infections of the liver
Individual subtypes of interferon-α (IFN-α) have been found to have different antiviral activity in different cell types and are therefore used to prevent or treat viral infections in cell types...
|
|
|
6008188 |
Cytokine potentiator and pharmaceutical formulation for cytokine administration
A cytokine activity enhancer comprising an ethanolamine derivative of the following general formula (I) or a salt thereof, or comprising it along with cytokine or a cytokine production promoter;...
|
|
|
6004549 |
Crystalline protein controlled release compositions
A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.
|
|
|
5997858 |
Stimulation of host defense mechanisms against tumors
A method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon...
|
|
|
5989839 |
Use of MOLT4 CD69 expression to determine the presence and activity of interferon inhibitors
Disclosed is a method of determining the presence and activity of interferon inhibitors in a test sample, preferably human blood serum. The method includes the steps of culturing cells which...
|
|
|
5985264 |
IL-12 Stimulation of Neonatal immunity
The present invention relates to a method of inducing a Th1-like response against a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and...
|
|
|
5981472 |
Methods for treating diseases
Herein is provided a method for identifying extreme stressors which may become causative agents responsible for syndromes characterized by premature progressive cell loss or cell over growth in an...
|
|
|
5980884 |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous...
|
|
|
5972331 |
Crystalline interferon alpha for pulmonary delivery and method for producing the same
A method to prepare crystalline interferon alpha suitable for aerosol formulation either for systemic or topical (inhaled) drug delivery. The bioavailable interferon is in the form of crystalline...
|
|
|
5958402 |
Antitumor therapy using ovine or bovine interferon-tau
The invention provides antitumor therapeutic methods employing bovine or ovine interferon-tau (IFN-τ) proteins and polypeptides. The IFN-τ proteins exhibit the antiviral and antiproliferative...
|
|
|
5951972 |
Stabilization of somatotropins and other proteins by modification of cysteine residues
The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing...
|
|
|
5942224 |
Therapeutic agent for cat respiratory diseases and method of treatment using the same
A method using a therapeutic agent for cat respiratory diseases which contains a human interferon as an effective ingredient. The therapeutic agent exerts a strong efficacy on cats with only a...
|
|
|
5942223 |
Antiviral therapy using ovine or bovine interferon-tau
The invention provides antiviral therapeutic methods employing bovine or ovine interferon-tau (IFN-τ) proteins and polypeptides. The IFN-τ proteins exhibit the antiviral and antiproliferative...
|
|
|
5939286 |
Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second...
|
|
|
5932208 |
Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
A therapeutical composition for use in humans, comprising a combination of at least one natural or recombinant and preferably human cytokine with at least one muramyl peptide selected from those...
|
|
|
5928639 |
Immunotherapy of cancer with allogeneic lymphocytes
Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant...
|
|
|
5928649 |
Method of reversing immunosuppression in vaccines
A method of reversing or preventing immunosuppression or antigenic interference associated with combination vaccines in mammals, is disclosed. Cytokines, or cytokine inducer, are administered in...
|
|
|
5910304 |
Low-dose oral administration of interferons
Improved methods for administering an interferon (IFN) to a warm-blooded vertebrate are described. The methods employ oral administration of the IFN to the vertebrate in very low dosages, for...
|
|
|
5885567 |
Treatment of infection in fowl by oral administration of avian interferon proteins
The present invention relates to a chicken interferon gene coding for the amino acid sequence of SEQ ID NO: 1. The present invention also relates to a method of producing biologically active...
|
|
|
5882640 |
Treatment of hyperallergenic response with oral interferon
Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral...
|
|
|
5874085 |
Vaccine for enhanced production of IgA antibodies
The invention describes compositions and methods for optimizing IgA class switching in B cells. The compositions comprise a multivalent antigen receptor crosslinker, CD40 ligand or...
|
|
|
5858690 |
Method for detecting allergy
The present invention comprises a simple way of identifying the tendency towards allergy or allergy already broken out, and showing the probability of allergy in a patient, by measuring the...
|
|
|
5849282 |
Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser.sup.71 !-interleukin-1β
This invention provides an anti-tumor agent and a method for treating a tumor wherein gamma-interferon and interleukin-1 are used as active ingredients.
|
|
|
5846526 |
Treatment of autoimmune disorders with oral interferon
Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in...
|
|
|
5830455 |
Method of treatment using a therapeutic combination of α interferon and free radical scavengers
The present invention relates to a therapeutic combination therapy involving the use of human interferon. The therapy involves the treatment of conditions susceptible to treatment with human...
|
|
|
5824300 |
Treatment of neoplastic disease with oral interferon
Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with...
|
|
|
5792451 |
Oral drug delivery compositions and methods
The present invention relates to an oral drug delivery system, and in particular to modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The...
|
|
|
5789375 |
Pernasal composition and pernasal preparation containing the same
A pernasal composition containing a pharmacologically active substance, water and an alcohol, wherein the alcohol content is 10-70 vol. % of the whole composition. This composition is highly safe...
|